Cancer drug combination ‘shrinks 60% of melanomas’
A pair of cancer drugs can shrink tumours in nearly 60% of people with advanced melanoma, a new trial has suggested.
An international trial on 945 patients found treatment with ipilimumab and nivolumab stopped the cancer advancing for nearly a year in 58% of cases.
UK doctors presented the data at the American Society of Clinical Oncology.
A new combination therapy for skin cancer, which scientists say could pave the way for once in a generation change in the way we treat all sorts of cancers.
Cancer Research UK said the drugs deliver a “powerful punch” against one of the most aggressive forms of cancer.
Melanoma, the most serious form of skin cancer, is the sixth most common cancer in the UK – it kills more than 2,000 people in Britain each year.
Harnessing the immune system is a rapidly developing field in cancer research.
The immune system is a powerful defence against infection. However, there are many “brakes” built-in to stop the system attacking our own tissues.
Posted on 14 June, 2015, in Blog, Research, Videos and tagged American Society of Clinical Oncology, BBC, Cancer Research UK, immune system, Little Fighters Cancer Trust, melanoma. Bookmark the permalink. Leave a comment.